Management of viral infections in AIDS patients
| Autor: | D H King, J L Drucker |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Microbiology (medical)
Herpesvirus 4 Human viruses medicine.medical_treatment Acyclovir Retinitis Opportunistic Infections Antiviral Agents Herpes Zoster Virus Zidovudine chemistry.chemical_compound Acquired immunodeficiency syndrome (AIDS) Humans Medicine Acquired Immunodeficiency Syndrome Chemotherapy Nucleoside analogue business.industry virus diseases Herpes Simplex General Medicine medicine.disease Virology Tumor Virus Infections Infectious Diseases chemistry Virus Diseases Cytomegalovirus Infections Immunology Viral disease Leukoplakia Oral business Thymidine medicine.drug |
| Zdroj: | Infection. 15:S32-S33 |
| ISSN: | 1439-0973 0173-2129 |
| DOI: | 10.1007/bf01650109 |
| Popis: | Viral infections, predominantly those of the herpes virus family, account for up to 16% of all clinically significant infections in AIDS patients. Acyclovir has provided successful treatment in AIDS patients suffering from severe herpes simplex and herpes zoster virus infections. Preliminary results are presented on newly developed acyclovir analogues. Desciclovir, an oral prodrug of acyclovir which is metabolized to acyclovir in vivo, allows treatment of virus infections per os, where high serum levels are needed, e.g. in Epstein-Barr virus infections. BW B759U, another analogue of acyclovir, has been used for the treatment of life-threatening or sight-threatening cytomegalovirus infections in AIDS patients. More than 80% of the patients treated for retinitis experienced stabilization or clinical improvement. Antiviral efficacy was demonstrated in 73% of the patients. Azidothymidine, a nucleoside analogue of thymidine, has been developed specifically to treat the HIV infection. Its antiviral activity is based on inhibition of reverse transcriptase. Phase I studies have demonstrated that azidothymidine is well tolerated. Its ability to cross the blood brain barrier makes it an attractive candidate for treatment of HIV. Trials to determine efficacy are in progress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink